Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XBB.2.3.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.2.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.15NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.2.3.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EU.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.2.3.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.4.11NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.7.14NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.25NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BN.1.2.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.16.26NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GJ.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CM.12NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DY.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.7.14.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.3.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DY.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.59NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.24.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.17.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.63NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.2.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GW.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.2.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.7.14.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.13.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.18NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.16NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.22NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HL.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.42.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DZ.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DZ.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.7.14.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DY.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.12NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.7.14.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.7.14.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BN.1.3.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
DY.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.2.48NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.2.49NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.7.14.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.2.3.11NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.4.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GY.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used